Intra-Cellular Therapies Files 8-K on Shareholder Vote Matters
| Field | Detail |
|---|---|
| Company | Intra-Cellular Therapies, Inc. |
| Form Type | 8-K |
| Filed Date | Mar 27, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: ITCI
TL;DR
ITCI filed an 8-K about a shareholder vote - details TBD.
AI Summary
Intra-Cellular Therapies, Inc. filed an 8-K on March 27, 2025, to report on the submission of matters to a vote of its security holders. The filing does not contain details about specific proposals or outcomes of any vote, but indicates that a shareholder vote is a subject of this report.
Why It Matters
This filing signals that important corporate decisions requiring shareholder approval are being addressed by Intra-Cellular Therapies, Inc.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose new financial or operational risks.
Key Players & Entities
- Intra-Cellular Therapies, Inc. (company) — Registrant
- March 27, 2025 (date) — Date of Report
FAQ
What specific matters were submitted for a vote of security holders?
The filing does not specify the exact matters submitted for a vote, only that such matters were presented.
When did the event requiring a shareholder vote occur or is it scheduled to occur?
The filing is dated March 27, 2025, and pertains to matters submitted as of that date.
What is the Commission File Number for Intra-Cellular Therapies, Inc.?
The Commission File Number is 001-36274.
Where is Intra-Cellular Therapies, Inc. incorporated?
The company is incorporated in Delaware.
What is the principal executive office address for Intra-Cellular Therapies, Inc.?
The principal executive offices are located at 135 Route 202/206 Suite 6, Bedminster, NJ 07921.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 27, 2025 regarding Intra-Cellular Therapies, Inc..